Pfizer (PFE +2.8%) trades up today on a solid Q4 report which benefited from a surge in profit...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer (PFE +2.8%) trades up today on a solid Q4 report which benefited from a surge in profit from the sale of its nutrition unit, and largely offset a 7% decline in its Lipitor sales due to generic competition. In its call, the company pointed to other drugs coming to market that it hopes will offset Lipitor, including Xeljanz, a new treatment for rheumatoid arthritis that was approved by the FDA in November, and Eliquis, an anticlotting drug that was cleared in late December. FY13 forecast brackets Street estimates.